Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 4/20 | 0.47 |
| ▸ | MGLL | Q99685 | 3/20 | 0.47 |
| ▸ | LIPE | Q05469 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28767248 | 0.86 | FAAH (0.53) | FAAHMGLLCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL389808 | 0.86 | CYP2C9 (0.54) | FAAHMGLLCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL388452 | 0.83 | FAAH (0.47) | FAAHMGLLCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL389995 | 0.82 | FAAH (0.43) | FAAHMGLLLIPECYP1A2CYP3A4 | |
| SCHEMBL388333 | 0.80 | FAAH (0.47) | TRPA1TRPV1FAAHMGLLCYP1A2 | |
| SCHEMBL391615 | 0.80 | CYP1A2 (0.46) | FAAHMGLLCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL389859 | 0.80 | NPY2R (0.48) | FAAHMGLL | |
| SCHEMBL391712 | 0.79 | GRIN2B (0.44) | FAAHCYP3A4CYP2C9 | |
| SCHEMBL1242760 | 0.77 | TRPV1 (0.53) | TRPA1TRPV1MGLLLIPE | |
| SCHEMBL392018 | 0.77 | MGLL (0.54) | FAAHMGLLCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101626-B2 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2004157-B1 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | ARENA PHARM INC (US) | 2011-01-12 | — | — | EP | disclosed |
| EP-2253311-A2 | Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto | Arena Pharmaceuticals, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7816364-B2 | GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080312281-A1 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes | PROSIDION LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080312281-A1 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes | PROSIDION LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| US-20080312281-A1 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes | PROSIDION LIMITED (GB) | 2008-12-18 | — | — | US | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190750-A1 | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto | GPR119, GLP1R, GPR4 | TRPA1 1272/4885TRPV1 456/4885FAAH 2029/4885 |
| US-20080312281-A1 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes | GPR119, GCGR, GPR65 | TRPA1 447/4885TRPV1 454/4885FAAH 579/4885 |
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | GPR119, GLP1R, GPR4 | TRPA1 1272/4885TRPV1 456/4885FAAH 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.